As filed with the Securities and Exchange Commission on October 18, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SANUWAVE Health, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | | | | |
| Nevada | | | | | 20-1176000 |
(State or other Jurisdiction of Incorporation or Organization) | | | | | (I.R.S. Employer Identification No.) |
11495 Valley View Road
Eden Prairie, Minnesota 55344
(Address of principal executive offices and zip code)
SANUWAVE Health, Inc. 2024 Equity Incentive Plan
(Full title of the plan)
| | | | | |
| Morgan C. Frank | |
| Chief Executive Officer | |
SANUWAVE Health, Inc. | |
| 11495 Valley View Road | |
| Eden Prairie, Minnesota 55344 | |
(952) 656-1029 | |
(Name, address and telephone number, including area code, of agent for service)
| | |
| Copies to: |
Ben A. Stacke |
| Griffin D. Foster |
| Faegre Drinker Biddle & Reath LLP |
| 2200 Wells Fargo Center |
| 90 South Seventh Street |
| Minneapolis, Minnesota 55402 |
| (612) 766-7000 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | | | | |
| | | | | |
Large accelerated filer ☐ | Accelerated filer ☐ |
Non-accelerated filer ☒ | Smaller reporting company ☒ Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
The stockholders of SANUWAVE Health, Inc. (the “Company”) approved the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) on August 7, 2024 (the “Effective Date”). The following shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), are available for issuance under the 2024 Plan: (a) 1,376,556 shares of Common Stock (the “New Shares”), and (b) up to 42,605 shares of Common Stock which were subject to outstanding awards under the Amended and Restated 2006 Stock Incentive Plan (the “2006 Plan”) as of the Effective Date (the “Outstanding Shares”). The Outstanding Shares will be available for future grants under the 2024 Plan to the extent that, on or after the Effective Date, such awards are forfeited, cancelled, settled, paid in cash, or expire before being exercised or settled in full. Upon stockholder approval of the 2024 Plan on the Effective Date, no new awards may be granted under the 2006 Plan.
The purpose of this Registration Statement is to register the New Shares and the Outstanding Shares. A post-effective amendment to the Company’s Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 3, 2010 (Registration Statement No. 333-170301) is being filed contemporaneously with the filing of this Registration Statement to deregister the 50,728 shares of Common Stock that were previously authorized for issuance under the 2006 Plan and that, as of the Effective Date, were not issued under the 2006 Plan and were not subject to outstanding awards granted under the 2006 Plan.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of Form S-8 are not required to be filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to the introductory Note to Part I of Form S-8 and Rule 424 under the Securities Act of 1933, as amended (the “Securities Act”). The documents containing the information specified in Part I will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| | | | | | | | | | | | | | | | | |
| | | | | |
| Item 3. | Incorporation of Documents by Reference. |
The following documents filed by the Company with the Commission are hereby incorporated by reference into this Registration Statement:
•the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 21, 2024;
•the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, filed with the Commission on May 9, 2024 and August 12, 2024, respectively;
•the Company’s Current Reports on Form 8-K filed (but not furnished) on January 3, 2024, January 25, 2024, February 21, 2024, February 28, 2024, March 7, 2024, April 1, 2024, April 26, 2024, June 3, 2024, June 4, 2024, June 21, 2024, June 26, 2024, July 17, 2024, August 9, 2024 and August 18, 2024; and
•the description of the Company’s Common Stock contained in the Company’s Registration Statement on Form 10-SB, as filed with the Commission on December 18, 2007, as updated by Exhibit 4.22 to the Company’s Form 10-K for the year ended December 31, 2019, and any and all amendments or reports filed for the purpose of updating such description.
In addition, all reports and other documents subsequently filed (but not furnished) by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of Common Stock offered hereby have been sold or that deregisters all shares of Common Stock then remaining unsold, shall be deemed to be incorporated by reference in and a part of this Registration Statement from the date of filing of such reports and documents; except as to any document, or portion of or exhibit to a document, that is “furnished” to (rather than “filed” with) the Commission.
Any statement contained in a document incorporated, or deemed to be incorporated, by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
| | | | | | | | | | | | | | | | | | | | |
| | | | | |
| Item 4. | Description of Securities. | |
Not applicable.
| | | | | | | | | | | | | | | | | |
| | | | | |
| Item 5. | Interests of Named Experts and Counsel. |
Not applicable.
| | | | | | | | | | | | | | | | | |
| | | | | | |
| Item 6. | Indemnification of Directors and Officers. |
The Nevada General Corporation Law (the “NGCL”) provides that a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless (i) such act or omission constituted a breach of his or her fiduciary duties as a director or officer, and (ii) his or her breach of those duties involved intentional misconduct, fraud or a knowing violation of law. Under the NGCL, a corporation may indemnify directors and officers, as well as other employees and individuals, against any threatened, pending or completed action, suit or proceeding, except an action by or in the right of the corporation, by reason of the fact that he or she is or was a director, officer, employee or
agent of the corporation so long as such person acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, does not, of itself, create a presumption that the person did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, or that, with respect to any criminal action or proceeding, he or she had reasonable cause to believe that his or her conduct was unlawful.
The NGCL further provides that indemnification may not be made for any claim as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that, in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper. To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding or in defense of any claim, issue or matter therein, the corporation must indemnify him or her against expenses, including attorney’s fees, actually and reasonably incurred in connection with the defense. The NGCL provides that this is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders, or disinterested directors or otherwise.
Our Bylaws (the “Bylaws”) and contractual arrangements with certain of the Company’s directors and officers provide that the Company is required to indemnify its directors and officers to the fullest extent permitted by law. The Bylaws and these contractual arrangements also require the Company to advance expenses incurred by a director or officer in connection with the defense of any proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not entitled to be indemnified by the Company. The Bylaws also permit the Company to purchase and maintain errors and omissions insurance on behalf of any director or officer for any liability arising out of his or her actions in a representative capacity. The Company does not presently maintain any such errors and omissions insurance for the benefit of its directors and officers.
| | | | | | | | | | | | | | | | | |
| | | | | |
| Item 7. | Exemption from Registration Claimed. |
Not applicable.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| Exhibit No. | | Description |
| | | |
| | Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Form 10-SB filed with the Commission on December 18, 2007). |
| | |
| | Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Appendix A to the Definitive Schedule 14C filed with the Commission on October 16, 2009). |
| | |
| | Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Exhibit A to the Definitive Schedule 14C filed with the Commission on April 16, 2012). |
| | Bylaws (Incorporated by reference to Exhibit 3.02 to the Form 10-SB filed with the Commission on December 18, 2007). |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
| | Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Company dated March 14, 2014 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the Commission on March 18, 2014). |
| | |
| | Certificate of Amendment to the Articles of Incorporation, dated September 8, 2015 (Incorporated by reference to Exhibit 3.6 to the Form 10-K filed with the Commission on March 30, 2016). |
| | |
| | Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock of the Company dated January 12, 2016 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the Commission on January 19, 2016). |
| | |
| | Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock of the Company dated January 31, 2020 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the Commission on February 6, 2020). |
| | Certificate of Designation of Series D Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the Commission on May 20, 2020). |
| | |
| | Certificate of Amendment of the Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the Commission on January 5, 2021). |
| | |
| | Certificate of Amendment of the Articles of Incorporation, dated January 31, 2023 (Incorporated by reference to Exhibit 3.12 to the Form S-1/A filed with the Commission on January 31, 2023). |
| | |
| | Certificate of Amendment of the Articles of Incorporation, effective as of October 18, 2024 (Incorporated by reference to Exhibit 3.2 to the Form 8-K filed with the Commission on October 18, 2024). |
| | |
| | SANUWAVE Health, Inc. 2024 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the Commission on August 9, 2024). |
| | |
| | Opinion of Hutchison & Steffen, PLLC |
| | | |
| | Consent of Hutchison & Steffen, PLLC (included in Exhibit 5.1) |
| | | |
| | Consent of Marcum LLP |
| | | |
| | Power of Attorney (included on signature page hereto) |
| | | |
| | Filing Fee Table |
| | | | | |
| | | | | | | | | | |
| Item 9. | Undertakings. |
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement;
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement; and
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(i) Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of Minnesota, on October 18, 2024.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| | SANUWAVE Health, Inc. | |
| | | |
| | By: | /s/ Morgan C. Frank | |
| | | Name: Morgan C. Frank Title: Chief Executive Officer | |
POWER OF ATTORNEY
We, the undersigned officers and directors of SANUWAVE Health, Inc., hereby severally constitute and appoint Morgan C. Frank and Peter Sorensen, and each of them, each with full power to act without the other, his true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement, and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto each of said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person hereby ratifying and confirming that each of said attorneys-in-fact and agents or his substitutes may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below on October 18, 2024 by the following persons in the capacities indicated.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Signature | | | | | | Title | |
| | |
/s/ Morgan C. Frank | | Chief Executive Officer and Chairman of the Board of Directors |
| Name: Morgan C. Frank | | (Principal Executive Officer) |
| | | |
/s/ Peter Sorensen | | Chief Financial Officer |
| Name: Peter Sorensen | | (Principal Financial Officer and Principal Accounting Officer) |
| |
Director |
| Name: Kevin A. Richardson, II | | |
| | |
/s/ A. Michael Stolarski | | Director |
| Name: A. Michael Stolarski | | |
| | | |
/s/ Jeffrey Blizard | | Director |
| Name: Jeffrey Blizard | | |
| | | |
/s/ Ian Miller | | Director |
| Name: Ian Miller | | |
| | | |
/s/ James Tyler | | Director |
| Name: James Tyler | | |
Exhibit 107
Calculation of Filing Fee Table
FORM S-8
(Form Type)
SANUWAVE Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| | | | | | | | | | | | | | | | | | | | | | | |
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | Common stock, $0.001 par value per share | Rule 457(c) and 457(h) | 1,419,161 (2) | $13.67 (3) | $19,399,930.87 | 0.00015310 | $2,970.13 |
| Total Offering Amounts | | – | | $2,970.13 |
| Total Fee Offsets | | | | – |
| Net Fee Due | | | | $2,970.13 |
(1) The aggregate number of shares to be registered is subject to adjustment by reason of stock splits, stock dividends and other events pursuant to the anti-dilution provision of the SANUWAVE Health Inc. (the “Company”) 2024 Equity Incentive Plan. Accordingly, pursuant to Rule 416, this Registration Statement covers, in addition to the number of shares of the Company’s common stock shown in the table above, an indeterminate number of shares of Company common stock that may become issuable by reason of such provision.
(2) Represents (i) 1,376,556 shares of Company common stock available for issuance under the 2024 Equity Incentive Plan (the “2024 Plan”) and (ii) up to 42,605 shares of Company common stock (the “Outstanding Shares”) which were subject to outstanding awards under the Amended and Restated 2006 Stock Incentive Plan as of August 7, 2024 (the “Effective Date”), the date that the Company’s stockholders approved the 2024 Plan. The Outstanding Shares will be available for future grants under the 2024 Plan to the extent that, on or after the Effective Date, such awards are forfeited, cancelled, settled, paid in cash, or expire before being exercised or settled in full.
(3) Estimated pursuant to Rule 457(c) and 457(h) of the Securities Act of 1933, as amended, solely for the purpose of calculating the registration fee, based upon the average of the bid and ask prices of shares of Company common stock on the OTCQB on October 16, 2024, as adjusted to reflect the 1-for-375 reverse stock split of the Company’s outstanding common stock effected on October 18, 2024.
| | | | | |
| Peccole Professional Park 10080 West Alta Drive, Suite 200 Las Vegas, Nevada 89145 702.385.2500 fax 702.385.2086 hutchlegal.com
|
October 18, 2024
Board of Directors
SANUWAVE Health, Inc.
11495 Valley View Road
Eden Prairie, Minnesota 55344
Re: SANUWAVE Health, Inc./Registration Statement on Form S-8
Ladies and Gentlemen:
We have acted as special Nevada counsel to SANUWAVE Health, Inc., a Nevada corporation (the “Company”), in connection with the preparation and filing with the United States Securities and Exchange Commission (“SEC”), on or about the date hereof, pursuant to the federal Securities Act of 1933, as amended (the “Securities Act”), of the Registration Statement on Form S-8 (the “Registration Statement”) covering the possible issuance under the Company’s 2024 Equity Incentive Plan approved on August 7, 2024 (the “2024 Plan”) of: (a) up to 1,376,556 shares of the Company’s common stock, $0.001 par value (“Common Stock”) (the “New Shares”); and (b) up to 42,605 shares of Common Stock which were subject to outstanding awards under the Company’s Amended and Restated 2006 Stock Incentive Plan as of August 7, 2024 (the “Outstanding Shares”, and collectively with the New Shares, the “Securities”), as described in the Registration Statement.
This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of SEC Regulation S-K (12 C.F.R. § 229.601(b)(5)).
In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of: (i) the Registration Statement; (ii) the Articles of Incorporation of the Company as filed with the Secretary of State of Nevada on May 6, 2004, as amended by that certain Certificate of Amendment as filed with the Secretary of State of Nevada on November 5, 2009, as amended by that certain Certificate of Amendment as filed with the Secretary of State of Nevada on May 29, 2012, as amended by that certain Certificate of Amendment as filed with the Secretary of State of Nevada on September 8, 2015, as amended by that certain Certificate of
SANUWAVE Health, Inc.
October 18, 2024
Page 2
Amendment as filed with the Secretary of State of Nevada on December 30, 2020, as amended by that certain Certificate of Amendment as filed with the Secretary of State of Nevada on January 31, 2023, and as amended by that certain Certificate of Amendment as filed with the Secretary of State of Nevada on October 15, 2024; (iii) the Bylaws of the Company; (iv) the 2024 Plan; (v) that certain unanimous written consent of the Board of Directors of the Company dated July 1, 2024; (vi) that certain unanimous written consent of the Compensation Committee and the Board of Directors of the Company dated August 28, 2024; and (vii) that certain Officer’s Certificate of the Company dated October 18, 2024. We also have examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates of public officials, certificates of officers or other representatives of the Company and others, and such other documents, certificates, and records as we have deemed necessary or appropriate as a basis for the opinions set forth herein.
In our examination we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as facsimile, electronic, certified, or photostatic copies. We have relied upon the accuracy and completeness of the information, factual matters, representations, and warranties contained in such documents. In our examination of documents, we have assumed that the parties thereto, other than the Company, had the power, corporate or other, to enter into and perform all obligations thereunder, and, other than with respect to the Company, the due authorization by all requisite action, corporate or other, the execution and delivery by all parties of the documents, and the validity and binding effect thereof on such parties.
Based upon and subject to the foregoing, we are of the opinion that:
(1)The Securities have been duly authorized and, upon issuance thereof pursuant to the terms of the 2024 Plan and any applicable award agreement, and when issued by the Company and, where applicable, paid for in accordance with the terms of the 2024 Plan and any applicable award agreement, will be validly issued, fully paid, and non-assessable.
We disclaim any undertaking to advise you of any changes in the facts stated or assumed herein or any changes in applicable law that may come to our attention subsequent to the date the Registration Statement is declared effective.
While certain members of this firm are admitted to practice in certain jurisdictions other than Nevada, in rendering the foregoing opinions we have not examined the laws of any jurisdiction other than Nevada. Accordingly, the opinions we express herein are limited to matters involving the laws of the State of Nevada (excluding securities laws). We express no opinion regarding the effect of the laws of any other jurisdiction or state, including any federal or state securities laws related to the issuance and sale of the Securities.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement, and we consent to the reference of our name under the caption “Legal Matters” in the prospectus forming a part of the Registration Statement. In giving the foregoing consent, we do not hereby admit
SANUWAVE Health, Inc.
October 18, 2024
Page 3
that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC thereunder.
Very truly yours,
/s/ HUTCHISON & STEFFEN, PLLC
HUTCHISON & STEFFEN, PLLC
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in this Registration Statement of SANUWAVE Health, Inc. on Form S-8 of our report dated March 21, 2024, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of SANUWAVE Health, Inc. as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, appearing in the Annual Report on Form 10-K of SANUWAVE Health, Inc. for the year ended December 31, 2023.
/s/ Marcum llp
Marcum llp
New York, NY
October 18, 2024
SANUWAVE Health (QB) (USOTC:SNWV)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
SANUWAVE Health (QB) (USOTC:SNWV)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
